期刊文献+

采用动态血糖监测系统评价沙格列汀改善胰岛β细胞功能较差的2型糖尿病患者血糖波动的观察 被引量:11

Evaluation of efficacy of saxagliptin on blood glucose fluctuations by CGMS in type 2 diabetic patients with poor β-cell function
原文传递
导出
摘要 目的 观察沙格列汀联合持续皮下输注胰岛素对胰岛β细胞功能较差的T2DM患者血糖波动的影响. 方法 选取胰岛功能较差的T2DM患者30例,采用持续皮下输注胰岛素治疗15d,第10天后不再调整胰岛素剂量,第13天晨起开始口服沙格列汀,第11~15天采用动态血糖监测系统(CGMS)监测血糖,比较第11~12天和第14~15天平均血糖波动幅度(MAGE)、血糖水平标准差(SD-BG)、最大血糖波动幅度(LAGE)、平均血糖水平(MBG)、血糖>10.0 mmol/L的时间百分率(PT10.0)、血糖<3.9 mmol/L时间百分率(PT3.9)的变化. 结果 与口服沙格列汀前相比,口服沙格列汀后MAGE [(5.28±1.44)vs(3.27±0.76)mmol/L,P<0.01]、SDBG[(2.43±0.50)vs(1.79±0.45) mmol/L,P<0.01]、MBG[(8.05±1.01) vs (6.94±0.72) mmol/L,P<0.01]、LAGE[(8.91±1.57) vs(6.77±1.13)mmol/L,P<0.01]、PT10.0[(11.69±4.18)%vs (4.03±2.50)%,P<0.01]下降,PT3.9[(4.07±3.00)%vs (4.72±2.66)%,P>0.05]变化比较差异无统计学意义. 结论 沙格列汀联合持续皮下输注胰岛素可改善胰岛功能较差的T2DM患者血糖波动,且不增加低血糖事件发生. Objective To evaluate the efficacy of saxagliptin on blood glucose fluctuations by continuous glucose monitoring system (CGMS) in long-course T2DM patients with poor β-cell function. Methods Thirty T2DM patients with poor β-cell function were treated with insulin-pump for fifteen days. The insulin dose was not adjusted after the tenth day, and saxagliptin was add-on to the previous therapy on the thirteenth to fifteenth days. CGMS was performed for the last five days. The mean amplitude of glycaemic excursion (MAGE), standard deviation of blood glucose ($DBG) and mean blood glucose (MBG), percentage period of hyperglycemia (glucose〉 10.0 mmol/L, PT10.0), percentage period of hypoglycemia (glucose〈3.9 mmol/L,PT3.9) of the patients on the eleventh to twelfth and fourteenth to fifteenth were compared. Results Compared with pre-administration of saxagliptin, the levels of MAGE [(5.28±1.44) vs (3.27_±0. 76)mmol/L,P〈0.01],SDBG [(2.43±0.50) vs (1.79±0.45)mmol/L,P〈 0.01],MBG [(8.05±1.01) vs (6.94±0.72)mmol/L,P〈0. 01],LAGE [(8. 91±1.57)vs(6. 77±1.13) mmol/L,P〈 0. 01 ], PT10.0 [( 11.69 ± 4.18 ) % vs (4.03 ± 2.50) %, P 〈 0.01] were significantly decreased. There was no significant difference on PT3.9 [(4.07±3.00)% vs (4.72± 2. 66)%, P〉 0. 05]. Conclusion Adding saxagliptin on long-course T2DM patients with poor β-cell function receiving insuiin-pump therapy is effective for improving glucose fluctuations without increasing the incidence of hypoglycemic events.
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2014年第12期1109-1112,共4页 Chinese Journal of Diabetes
基金 广东省科技计划项目(2011B010500027)
关键词 沙格列汀 动态血糖监测系统 血糖波动 糖尿病 2型 Saxagliptin Continuous glucose monitoring system (CGMS) Glucose fluctuations Diabetes mellitus, type 2
  • 引文网络
  • 相关文献

参考文献10

  • 1Xu Y,Wang L,He J,et al.Prevalence and control of diabetes in Chinese adults.JAMA,2013,310:948-959. 被引量:1
  • 2U.K.prospective diabetes study 16.Overview of 6 years' therapy of type Ⅱ diabetes:a progressive disease.U.K.Prospective Diabetes Study Group.Diabetes,1995,44:1249-1258. 被引量:1
  • 3Tatosian DA,Guo Y,Schaeffer AK,et al.Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin,sitagliptin,or vildagliptin.Diabetes Ther,2013,4:431-442. 被引量:1
  • 4Rizzo MR,Barbieri M,Marfella R,et al.Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes:role of dipeptidy[peptidase-inhibition.Diabetes Care,2012,35:2076-2082. 被引量:1
  • 5Hari KK,Shaikh A,Prusty P.Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes:a randomized,open label study.Diabetes Res Clin Pract,2013,100:e55-e58. 被引量:1
  • 6Zhou J,Li H,Ran X,et al.Reference values for continuous glucose monitoring in Chinese subjects.Diabetes Care,2009,32:1188-1193. 被引量:1
  • 7Barbieri M,Rizzo MR,Marfella R,et al.Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-Ⅳ inhibitors.Atherosclerosis,2013,227:349-354. 被引量:1
  • 8Seaquist ER,Miller ME,Bonds DE,et al.The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study.Diabetes Care,2012,35:409-414. 被引量:1
  • 9Barnett AH,Charbonnel B,Donovan M,et al.Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.Curr Med Res Opin,2012,28:513-523. 被引量:1
  • 10Hare KJ,Vilsboll T,Asmar M,et al.The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.Diabetes,2010,59:1765-1770. 被引量:1

同被引文献142

  • 1李文娟,孙宇,刘金波,侯新国,陈丽.新诊断2型糖尿病患者动脉粥样斑块的发病情况及危险因素研究[J].山东大学学报(医学版),2009,47(7):85-88. 被引量:6
  • 2谷伟军,陆菊明,杨国庆,郭清华,窦京涛,母义明,潘长玉.甲钴胺及叶酸治疗对2型糖尿病同型半胱氨酸硫内酯解酶活性和血浆同型半胱氨酸水平的影响[J].中华医学杂志,2007,87(4):256-258. 被引量:22
  • 3Green BD,Irwin N,Gault VA,et al. Development and ther-apeutic potential of incretin hormone analogues for type 2diabetes [J]. The British Journal of Diabetes and VascularDisease, 2005,5(3):134-140. 被引量:1
  • 4Tatosian DA,Guo Y,Schaeffer AK,et al. Dipeptidyl pep-tidase-4 inhibition in patients with type 2 diabetes treatedwith saxagliptin, sitagliptin, or vildagliptin[J]. Diabetes Ther-apy,2013,4(2) :431-442. 被引量:1
  • 5Defronzo RA,Hissa MN,Garber AJ,et al. The efficacy andsafety of saxagliptin when added to metformin therapy inpatients with inadequately controlled type 2 diabetes withmetformin alone[J]. Diabetes Care, 2009,32(9) : 1649-1655. 被引量:1
  • 6Goke B,Gallwitz B,Eriksson J,et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mel-litus inadequately controlled on metformin alone:A 52-week randomised controlled trial[J]. International Journalof Clinical Practice,2010,64(12): 1619-1631. 被引量:1
  • 7Chacra AR, Tan GH, Apanovitch A , et al. Saxagliptinadded to a submaximal dose of sulphonylurea improvesglycaemic control compared with uptitration of sulphony-lurea in patients with type 2 diabetes : A randomised con-trolled trial [J]. International Journal of Clinical Practice,2009,63(9):1395-1406. 被引量:1
  • 8Soliman AT,Yasin M,EPAwwa A,et al. Detection of glycemicabnormalities in adolescents with beta thalassemia using contin uous glucose monitoring and oral glucose tolerance in adolescents and young adults with β- thalassemia major: Pilot study. Indian J Endocrinol Metab, 2013,17: 490-495. 被引量:1
  • 9Tu YT, Zhou Z. The application prospect of Glp-1 analogues and DPP-4 inhibitors in type 1 diabetes[ J]. Guangdong Medical Jour- nal ,2012,33 ( 18 ) :2705-2708. 被引量:1
  • 10Hoist JJ, Vilsb 11 T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus [J ]. Molecular and Cellular Endocri- nology,2009,297( 1 ) :127-136. DOI: 10. 1016/j. race. 2008.08. 012. 被引量:1

引证文献11

二级引证文献104

;
使用帮助 返回顶部